A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2011

Conditions
Uterine Cancer
Interventions
DRUG

Paclitaxel ,Carboplatin , Megesterol Acetate

Paclitaxel will be administered at an appropriate dose (175mg/m2) as a 3 hour continuous IV infusion every 21 days. Carboplatin will be administered at an appropriate dose utilizing Calvert formula for determining the area under the curve (AUC) based on the patient's glomerular filtration rate. Megesterol Acetate will be given orally four times a day at an anti-tumor dosage of 40 mg. This will be given for a total of 6 cycles over 18 weeks with the Megace continuing for 5 years as long as no evidence of recurrence is present.

Trial Locations (1)

35233

UAB Women's and Infant Center, 1700 6th Ave S, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER

NCT00584857 - A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer | Biotech Hunter | Biotech Hunter